#462: Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy
Quality ID 462
eMeasure ID CMS645v1
High Priority Measure No
Measure Type Process
Specialty General Oncology Urology
Measure descriptionPatients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater (indicated by HCPCS code) and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT.